obesity drugs glp-1 news today Market Overview: Agonists and the Market | Blog GLP-1 obesity drugs cleared of
Description
The STEP-HFpEF DM trial investigated whether the changes in glucose levels in HFpEF patients with obesity moderates the treatment benefits of GLP-1 RAs
(2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
The remaining authors declare not conflicts of interest
While universal deprescribing is unlikely to drive optimal results, it may make sense on an individual basis to explore discontinuation, lowering the dose, or increasing time between doses, as patients enter a maintenance phase with their treatment
Wegovy Important Safety Information: Read more about serious warnings and safety info
[ref] Circadian control of response to GLP-1: Like many hormones, there is a circadian aspect to GLP-1
